$BBIO — FinTwit mentions on Surfaced

$BBIO — FinTwit mentions on Surfaced

Recent mentions

16 mentions

@pelositrackerJul 9, 2026 · 2:51 PM

This is why we do it Back in April, we flagged Cisneros buying $BBIO ahead of an FDA decision Today, a rival company's heart drug failed a major clinical trial. That leaves BridgeBio as one of the only approved treatments for the same patients Since that tweet, it's up ~20% and just hit all time highs He still hasn't sold his pharma picks: • $AGIO is up +27% • $RARE is up +50% since the tweet

@adamfeuersteinJul 9, 2026 · 1:39 PM

What a day for ATTR-CMians... $AZN $IONS Wainua ouch. Thanks for playing. You're out. $ALNY Amvuttra, the silencer stands alone. But wither nucresiran? $BBIO Attruby sheds a competitor and the "stabilizer first" narrative get a boost.

@adamfeuersteinJul 9, 2026 · 9:37 AM

AstraZeneca $AZN, Ionis $IONS report major trial failure with heart disease drug Wainua fails in ATTR-CM, $ALNY + 16% $BBIO +12% https://t.co/41qJuUo6Uv via @DrewQJoseph

@adamfeuersteinJul 6, 2026 · 8:44 PM

$CRNX is a commercial stage biotech that was significantly underperforming the $XBI this year, similar to $INSM $MDGL $ALNY $BBIO Crinetics just acquired for a 100% premium by $VRTX. Unlike those other companies, it's stock also underperformed last year. Congrats to @Biohazard3737 - great call. Patience paid off.

@adamfeuersteinMay 19, 2026 · 12:43 PM

Good morning from SF. STAT’s #STATbreakthrough live event kicks off in a few hours. I’ll be chatting with $BBIO Neil Kumar and $INSM Will Lewis. Any questions? Drop them here. https://t.co/mhCQhxVJyF

@adamfeuersteinMay 7, 2026 · 8:05 PM

$BBIO Q1 Attruby sales $180 M

@adamfeuersteinMay 7, 2026 · 3:52 PM

Today is an opportune moment to mention STAT's next live event in San Francisco on May 19. I will be chatting on stage with $INSM CEO Will Lewis and $BBIO CEO Neil Kumar. Full agenda and registration here: https://t.co/YtXTTuz1Nv

@adamfeuersteinApr 28, 2026 · 1:23 PM

Third and final $PFE tafamidis patent lawsuit dismissed. $BBIO up

@pelositrackerApr 8, 2026 · 3:15 PM

New: Gil Cisneros (D) just filed up to $1,300,000 of new stock trades The ones that stood out are 3 pharma picks: $AGIO, $BBIO, and $RARE The crazy part is that all 3 had major FDA decisions go their way within weeks. every stock is up 10-26% Cisneros doesn't sit on a single health committee but 3/3 on FDA decisions is pretty good

@adamfeuersteinMar 10, 2026 · 3:44 PM

$BBIO $ALNY moving higher on apparently good news re: Pfizer's tafamidis patent defense. If you have access to Umer Raffat's research, he has all the details.

@adamfeuersteinFeb 24, 2026 · 8:07 PM

$IBRX $12B market cap, on par w $BMRN, just behind $BBIO $NBIX and larger than $JAZZ $MDGL Your 2026 biotech meme stock...

@adamfeuersteinFeb 12, 2026 · 12:37 PM

BridgeBio $BBIO drug for genetic cause of dwarfism succeeds in key study This is the third consecutive Phase 3 success for BridgeBio. It also could spell trouble for $BMRN's competing dwarfism drug. https://t.co/mwnbVetPFy via @damiangarde

@investmentguru_Jan 6, 2026 · 12:48 AM

The Fastest Growing Companies Heading Into 2026 From AI infrastructure and space to biotech, energy, and digital assets, these companies are where real growth is showing up on the tape: Top Performers $NBIS $PTGX $FLY $MP $LUNR AI, Crypto & Infrastructure Leaders $CRWV, $WULF, $IREN, $HUT, $CORZ, $CIFR, $BTDR $NVDA still dominant $ALAB, $AAOI, $SKYT — Chips & connectivity Biotech Breakouts $INSM, $SNDX, $ZYME, $ASND, $BBIO, $AXSM, $RYTM, $MDGL Clinical wins = asymmetric upside Energy, Mining & Industrials $USAS, $ARMN, $NGD, $TLN, $MP $DQ Speculative Growth $LCID, $NIO, $LMND, $RKT — High risk, high torque Space & Defense $RKLB, $RDW, $GEMI, $CDLR — Multi-year contracts + government spend $PLTR — AI + defense + enterprise scale 2026 won’t reward diversification — it will reward conviction, timing, and theme alignment. You don’t need 40 stocks. You need 3–5 leaders in megatrend sectors — and the patience to let compounding do the work. Follow the growth, not the noise.

@adamfeuersteinOct 29, 2025 · 11:12 AM

$BBIO Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1 https://t.co/R6UndoW0DS

@adamfeuersteinOct 27, 2025 · 11:02 AM

BridgeBio $BBIO study data on drug for rare form of muscular dystrophy could set up approval https://t.co/S4LRPEh4sb via @Jasonmmast

@adamfeuersteinSep 11, 2025 · 7:06 PM

It's getting testy, per Bloomberg... BridgeBio $BBIO Says Pfizer $PFE, Alnylam $ALNY Aren’t Playing Fair in Blockbuster Race https://t.co/ckse5iY2Jv